• Industry spotlight
• Genomics

Can DNA markers improve cancer testing?

Exact Sciences’ stool-based DNA testing kit was used to screen 1.2 million people in the first quarter of the year.

30 May 2023

• Updates
• Biotechnology
• Genomics

Will biotech M&A boost Pfizer shares?

Flush with cash from selling Covid-19 vaccines, big pharma firms are on the hunt for buy-out targets.

17 Apr 2023

• News
• Biotechnology
• Genomics

Oxford Nanopore scores higher revenues and smaller losses in 2022

The UK-based DNA sequencing company’s results are moving in the right direction, but Oxford Nanopore stock traded down as much as 7.5% the day after earnings call.

23 Mar 2023

• Updates
• Biotechnology
• Immunology
• Genomics

Carl Icahn strikes again as biotech stocks heat up

Moderna, Provention Bio and Illumina’s shares jump, although the latter is facing a proxy battle with activist investor Carl Icahn.

21 Mar 2023

• Updates
• Biotechnology
• Genomics
• Electric vehicles
• Solar

Top Stories

Pfizer shares boosted by $43bn Seagen deal

The US pharma giant, which already has 24 approved cancer medicines, is acquiring Seagen for $229 per share.

14 Mar 2023

• News
• Immunology
• Genomics
• Biotechnology

Will RSV vaccine race boost the GSK share price?

FDA advisory committee votes in favour of GSK’s RSV vaccine candidate.

07 Mar 2023

• Updates
• Biotechnology
• Health & wellness
• Genomics
• Immunology

GSK, Pfizer and Amgen grapple with a post-pandemic slump

Mixed results from these three pharma giants come amid a drop-off in Covid-related demand, although geriatric care may pick up the slack.

02 Feb 2023

• Fund watch
• Biotechnology
• Genomics

Positive biotech outlook lifts ARK Genomic Revolution ETF shares

The ARK Genomic Revolution ETF has shown strong performance recently with its largest holdings pushing the fund higher after a challenging two years.

23 Jan 2023